Article Text

Download PDFPDF
P172 Preclinical evidences of the therapeutic potential of ABTL0812 in endometrial cancer
  1. A Gil-Moreno1,
  2. I Felip2,
  3. CP Moiola3,
  4. C Megino-Luque4,
  5. C Lopez-Gil5,
  6. S Cabrera6,
  7. S Solé-Sánchez7,
  8. P Muñoz-Guardiola8,
  9. E Megias-Roda8,
  10. H Pérez-Montoyo7,
  11. J Alfon7,
  12. MY-V Yeste-Velasco7,
  13. M Santacana9,
  14. X Dolcet9,
  15. A Reques10,
  16. A Oaknin11,
  17. V Rodríguez-Freixinos11,
  18. JML Lizcano12,
  19. C Domènech7,
  20. X Matias-Guiu13,
  21. E Colas14 and
  22. N Eritja9
  1. 1Gynecological Oncology Department, CIBERONC., Hospital Universitari Vall d’Hebron, Barcelona
  2. 2Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, Lleida
  3. 3Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, CIBERONC, Universitat Autònoma de Barcelona, Barcelona
  4. 4Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Lleida
  5. 5Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, CIBERONC, Universitat Autònoma de Barcelona, Universitat Autònoma de Barcelona
  6. 6Gynecological Oncology Department, Vall Hebron University Hospital, CIBERONC, Vall Hebron University Hospital
  7. 7Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona
  8. 8Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Protein Kinases and Signal Transduction Laboratory, Institut de Neurociències and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona
  9. 9Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, University of Lleida
  10. 10Pathology Department, Vall Hebron University Hospital, Vall Hebron University Hospital
  11. 11Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital
  12. 12Protein Kinases and Signal Transduction Laboratory, Institut de Neurociències and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona
  13. 13Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, University of Lleida
  14. 14Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, CIBERONC, Universitat Autònoma de Barcelona, Lleida, Spain

Abstract

Introduction/Background Endometrial cancer (EC) is the most frequent of the infiltrating tumors of female genital tract. Surgical and adjuvant treatments are the cornerstone treatment for EC patients, however, the response rate to standard therapy is very limited, highlighting the need for novel and efficient treatments. ABTL0812, a small first-in-class molecule, induces cancer cell death by inhibiting the PI3K/AKT/mTOR pathway (frequently overactivated in EC) and inducing endoplasmic reticulum stress (ER-Stress).

Objective Assess the preclinical efficacy of ABTL0812 in EC.

Methodology We studied ABTL0812 treatment on viability, autophagy and apoptosis in a wide panel of EC cell lines and in 3D-murine endometrial organoids. ABTL0812 efficacy was evaluated in tumor onset and progression in a tamoxifen-inducible PTEN-KO murine model and cell line- or patient-derived xenograft (PDX) models. TRIB3 mRNA levels were evaluated in blood from EC patients recruited in ongoing Phase 1b/2a clinical trial.

Results We demonstrated that ABTL0812 treatment in vitro reduced viability, sensitized cancer cells and induced autophagy through ER-stress induction and PI3K/AKT/mTORC1 axis inhibition. In murine PTEN-KO cells, ABTL0812 decreased proliferation and induced nuclear fragmentation/condensation and caspase activation. ABTL0812 in vivo therapeutic benefit was confirmed, leading to a marked reduction in tumor growth (p<0.05), impairing the initial progression of endometrial tumorigenesis in PTEN-KO mouse model, and inhibiting tumor progression in PDX models, potentiating carboplatin-paclitaxel treatment. Finally, ABTL0812 increased TRIB3 mRNA levels after 8h of treatment in blood of human patients.

Conclusion Our results demonstrated that ABTL0812 treatment promoted autophagy followed by activation of the pro-apoptotic pathway. Collectively, we provided strong preclinical evidences of the therapeutic benefit of ABTL0812 as monotherapy or in combination with current first-line treatment in EC. Our findings present a novel and clinically applicable therapeutic strategy for EC and suggest the potential use of TRIB3 as a pharmacodynamic biomarker to monitor ABTL0812 treatment.

Disclosure Sonia Solé-Sánchez, Pau Muñoz-Guardiola, Elisabet Megias-Roda, Héctor Pérez-Montoyo, José Alfon, Marc Yeste-Velasco, Carles Domènech are Ability Pharmaceuticals employees. Carles Domènech CD holds shares of the Company. José Miguel Lizcano is member of its Scientific Advisory Board. Antonio Gil-Moreno, Isidre Felip, Cristian Pablo Moiola, Cristina Megino-Luque, Carlos Lopez-Gil, Silvia Cabrera, María Santacana, Xavier Dolcet, Armando Reques, Ana Oaknin, Victor Rodríguez-Freixinos Xavier Matias-Guiu, Eva Colas, Nuria Eritja, declare no conflicts of interest.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.